147 related articles for article (PubMed ID: 25530344)
1. Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Rashidi A; Sorscher SM
Leuk Lymphoma; 2015; 56(8):2468-9. PubMed ID: 25530344
[No Abstract] [Full Text] [Related]
2. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Bracht LK; Wen P; Meyerhardt JA; Kulke MH; Hornick JL; Redston M; LaFrankie DC; Black PM; Kesari S; Norden A; Drappatz J
J Clin Oncol; 2008 Oct; 26(29):4843-4. PubMed ID: 18779600
[No Abstract] [Full Text] [Related]
3. Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Wu YL; Raj N; Reidy-Lagunes D
Pancreas; 2020 Jan; 49(1):e14-e16. PubMed ID: 31856101
[No Abstract] [Full Text] [Related]
4. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Okusaka T; Ueno H; Morizane C; Kondo S; Sakamoto Y; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):628-33. PubMed ID: 25940377
[TBL] [Abstract][Full Text] [Related]
5. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Dufour C; Da Costa L; Auger N; Jullien M; Bhangoo R; Grill J
J Pediatr Hematol Oncol; 2008 Nov; 30(11):857-9. PubMed ID: 18989164
[TBL] [Abstract][Full Text] [Related]
7. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
[TBL] [Abstract][Full Text] [Related]
8. Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Raymond E; Dreyer C; Faivre S
Target Oncol; 2012 Sep; 7(3):151-2. PubMed ID: 22918794
[No Abstract] [Full Text] [Related]
9. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
10. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.
Brieau B; Hentic O; Lebtahi R; Palazzo M; Ben Reguiga M; Rebours V; Maire F; Hammel P; Ruszniewski P; Fenaux P
Endocr Relat Cancer; 2016 May; 23(5):L17-23. PubMed ID: 26932783
[No Abstract] [Full Text] [Related]
11. 10 questions about temozolomide and the treatment of brain tumors.
Pruitt AA; Rosenfeld MR
Neurologist; 2005 Nov; 11(6):362-5. PubMed ID: 16286879
[No Abstract] [Full Text] [Related]
12. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
13. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Schwarzberg AB; Stover EH; Sengupta T; Michelini A; Vincitore M; Baden LR; Kulke MH
Cancer Invest; 2007 Jun; 25(4):249-55. PubMed ID: 17612935
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Olsen IH; Sørensen JB; Federspiel B; Kjaer A; Hansen CP; Knigge U; Langer SW
ScientificWorldJournal; 2012; 2012():170496. PubMed ID: 22973169
[TBL] [Abstract][Full Text] [Related]
15. Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
Benjelloun A; Delavelle J; Lazeyras F; Dietrich PY
Neurology; 2001 Nov; 57(10):1932-3. PubMed ID: 11723300
[No Abstract] [Full Text] [Related]
16. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Cives M; Ghayouri M; Morse B; Brelsford M; Black M; Rizzo A; Meeker A; Strosberg J
Endocr Relat Cancer; 2016 Sep; 23(9):759-67. PubMed ID: 27552969
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Koumarianou A; Kaltsas G; Kulke MH; Oberg K; Strosberg JR; Spada F; Galdy S; Barberis M; Fumagalli C; Berruti A; Fazio N
Neuroendocrinology; 2015; 101(4):274-88. PubMed ID: 25924937
[TBL] [Abstract][Full Text] [Related]
18. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of temozolomide in patients with myelodysplastic syndrome.
Seiter K; Liu D; Siddiqui AD; Lerner R; Nelson J; Ahmed T
Leuk Lymphoma; 2004 Jun; 45(6):1209-14. PubMed ID: 15360003
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Su YW; Chang MC; Chiang MF; Hsieh RK
J Neurooncol; 2005 Feb; 71(3):315-8. PubMed ID: 15735923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
